Intraductal Papillary Mucinous Neoplasia (IPMN)

  • Scott Bussom Pharmacology Department, Yale University School of Medicine. New Haven, CT, USA
  • Muhammad Wasif Saif Yale Cancer Center, Yale University School of Medicine. New Haven, CT, USA
Keywords: Carcinoma, Pancreatic Ductal, Cytokines, Early Detection of Cancer, T-Lymphocytes, Regulatory


The diagnosis and treatment of intraductal papillary mucinous tumors (IPMN) of the pancreas has evolved over the last decade. IPMN is a disease of the ductal epithelium and represent a spectrum of disease, ranging from benign to malignant lesions, making the early detection and characterization of these lesions important. As with villous adenomas of the colon, not all IPMNs will develop into adenocarcinoma. Definitive management is surgical resection for appropriate candidates, as benign lesions harbor malignant potential. Growing controversy revolves around issues of natural history, management of small-branch-duct lesions, ability to predict malignancy and/or progression, and surveillance strategies. Given these controversies, novel methods are needed to help in detecting and classifying IPMNs’ malignant potential so that appropriate treatment can be administered. The authors review abstracts from the 2010 ASCO Gastrointestinal Cancers Symposium held in January 2010, including biomarkers helping to classify IPMNs: IL-8 and IL-1beta from IPMN cyst aspirates (Abstract #133), and Foxp3/CD4/CD25 cells (Abstract #148) in peripheral blood. Future studies will hopefully provide insight into the many unanswered questions.

Image: Hypothetical progression of IPMN to adenocarcinoma (Reproduced and modified by permission from Cancer Control, journal of the Moffitt Cancer Center)


Download data is not yet available.


Andrejevic-Blant S, Kosmahl M, Sipos B, Klöppel G. Pancreatic intraductal papillary-mucinous neoplasms: a new and evolving entity. Virchows Arch 2007; 451:863-9. [PMID 17899180] (FULL TEXT:

Ohashi K, Murakami Y, Murayama M, Taketoshi T, Ohta T, Ohashi I. Four cases of mucin-secreting cancer of the pancreas on specific findings of the papilla of Vater. Prog Dig Endosc 1982; 20:348.

Winter JM, Cameron JL, Campbell KA, Arnold MA, Chang DC, Coleman J, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg 2006; 10:1199-210. [PMID 17114007] (FULL TEXT:

Kloppel G, Solcia E, Longnecker DS, Capella C, Sobin LH. International histological typing of tumors of the exocrine pancreas. Springer, Berlin 1996.

Longnecker DS, Adler G, Hruban RH, Kloppel G. Intraductal papillary mucinous neoplasms. In: Hamilton SR, Aaltonen LA (eds): World Health Organization Classification of Tumors Pathology and Genetics of Tumors of the Digestive System Lyon, IARC Press, 2000, pp 237-241.

Tseng JF, Fernandez-del Castillo C, et al. The cystic neoplasms of the pancreas. In: Blumgart H, Editor, Surgery of the liver, biliary tract, and pancreas, Saunders, London (2006).

Salvia R, Fernández-del Castillo C, Bassi C, Thayer SP, Falconi M, Mantovani W, et al. Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. Ann Surg 2004; 239:678-85. [PMID 15082972] (FULL TEXT:

Tanno S, Nakano Y, Nishikawa T, Nakamura K, Sasajima J, Minoguchi M, et al. Natural history of branch duct intraductal papillary-mucinous neoplasms of the pancreas without mural nodules: long-term follow-up results. Gut 2008; 57:339-43. [PMID 17660227] (FULL TEXT:

Adsay NV, Volkan N. Intraductal Papillary Mucinous neoplasms of the pancreas from pathogenesis to pathology. Digestive Diseases Week. 2005. (FULL TEXT:

Maker AV, Brennan MF, DeMatteo RP, D'Angelica MI, Fong Y, Jarnagin WR, Allen P. Cyst fluid cytokines to distinguish low- and high-risk intraductal papillary mucinous neoplasms (IPMN). 2010 ASCO Gastrointestinal Cancers Symposium. Abstract No. 133. (FULL TEXT:

Ikemoto T, Shimada M, Utsunomiya T, Imura S, Morine Y, Hanaoka J, et al. Evaluation of Foxp3/CD4/CD25/t cell (Treg) in peripheral blood as a biomarker for the aggressiveness of intraductal papillary mucinous neoplasm. 2010 ASCO Gastrointestinal Cancers Symposium. Abstract No. 148. (FULL TEXT:

Hiraoka N, Onozato K, Kosuge T, Hirohashi S. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 2006; 12:5423-34. [PMID 17000676] (FULL TEXT:

Ikemoto T, Yamaguchi T, Morine Y, Imura S, Soejima Y, Fujii M, et al. Clinical roles of increased populations of Foxp3+CD4+ T cells in peripheral blood from advanced pancreatic cancer patients. Pancreas 2006; 33:386-90. [PMID 17079944] (FULL TEXT:

Hruban RH, Goggins M, Parsons J, Kern SE. Progression model for pancreatic cancer. Clin Cancer Res 2000; 6:2969-72. [PMID 10955772] (FULL TEXT:

Kimura W, Makuuchi M, Kuroda A. Characteristics and treatment of mucin-producing tumor of the pancreas. Hepatogastroenterology 1998; 45:2001-8. [PMID 9951854]

Yamao K, Ohashi K, Nakamura T, Suzuki T, Shimizu Y, Nakamura Y, et al. The prognosis of intraductal papillary mucinous tumors of the pancreas. Hepatogastroenterology 2000; 47:1129-34. [PMID 11020896]

Maffini MV, Calabro JM, Soto AM, Sonnenschein C. Stromal regulation of neoplastic development: age-dependent normalization of neoplastic mammary cells by mammary stroma. Am J Pathol 2005; 167:1405-10. [PMID 16251424] (FULL TEXT:

Hsiao YW, Liao KW, Hung SW, Chu RM. Tumor-infiltrating lymphocyte secretion of IL-6 antagonizes tumor-derived TGF-beta 1 and restores the lymphokine-activated killing activity. J Immunol 2004; 172:1508-14. [PMID 14734728] (FULL TEXT:

Yu P, Lee Y, Liu W, Krausz T, Chong A, Schreiber H, Fu YX. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med 2005; 201:779-91. [PMID 15753211] (FULL TEXT:

Correa-Gallego C, Warshaw AL, Fernandez-del Castillo C. Fluid CEA in IPMNs: A useful test or the flip of a coin? Am J Gastroenterol 2009; 104:796-7. [PMID 19223886] (FULL TEXT:

Pais SA, Attasaranya S, Leblanc J, Sherman S, Mchenry L, Schmidt M, Dewitt J. Utility of EUS-FNA and cyst fluid analysis in the diagnosis of intraductal papillary mucinous tumors: correlation with histopathology in 74 patients. Gastrointest Endosc 2006; 63:AB268. (FULL TEXT:

Kiriyama S, Hayakawa T, Kondo T, Shibata T, Kitagawa M, Ono H, Sakai Y. Usefulness of a new tumor marker, Span-1, for the diagnosis of pancreatic cancer. Cancer 1990; 65:1557-61. [PMID 2311067] (FULL TEXT:

Chung YS, Ho JJ, Kim YS, Tanaka H, Nakata B, Hiura A, et al. The detection of human pancreatic cancer-associated antigen in the serum of cancer patients. Cancer 1987; 60:1636-43. [PMID 3476183] (FULL TEXT:

Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 2007; 33:266-70. [PMID 17097848] (FULL TEXT:

Gold DV, Modrak DE, Ying Z, Cardillo TM, Sharkey RM, Goldenberg DM. New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis. J Clin Oncol 2006; 24:252-8. [PMID 16344318] (FULL TEXT:

Klapman J, Malafa MP. Early detection of pancreatic cancer: why, who, and how to screen. Cancer Control 2008; 15:280-7. [PMID 18813195] (FULL TEXT:

Hypothetical progression of IPMN to adenocarcinoma
How to Cite
BussomS., & SaifM. (2010). Intraductal Papillary Mucinous Neoplasia (IPMN). JOP. Journal of the Pancreas, 11(2), 131-134.
Highlights from the “2010 ASCO Gastrointestinal Cancers Symposium”. Orlando, FL, USA. January 22-24, 2010

Most read articles by the same author(s)